Connect with us

Business

Zynerba Pharmaceuticals (NASDAQ: ZYNE) Announces Its Position in the Development of the First FDA Approved Treatment for Patients with Fragile X Syndrome

Published

on

For the longest time possible, rare and near-rare neuropsychiatric conditions have had very few treatment options. Today, many patients and their families have lost hope, are feeling hopeless and lonely. However, Zynerba Pharmaceuticals (NASDAQ: ZYNE) has produced transdermal cannabinoid therapies expected to offer solutions to these conditions. 

And while announcing its Q1 2021 financial results, it is clear the company is making positive impacts. The results outline a $93.1 million in cash and cash equivalents above the $59.2 million as of December 31, 2020. Other operational highlights in the Q1 report included initiating a confirmatory pivotal Phase 3 trial of RECONNECT, a potential treatment for patients with Fragile X syndrome. 

Meanwhile, the company says it has resumed screening patients for the 14-week open-label Phase 2 INSPIRE trial following the easing of COVID-19-related restrictions in Australia. It is also seeking an audience with the FDA to discuss data supporting the potential efficacy of Zygel in Autism Spectrum Disorder (ASD). 

The Development Efforts on CBD vs. the Positive Effects in the Central Nervous System

Disorders originating from the nervous system attribute to the presence of Neuropsychiatric conditions. Their severe cognitive and behavioral manifestation primarily affect a person’s ability to learn, interact, work and emotionally cope with stress. Meaning they hit hard on the Central Nervous System. 

Cannabinoids interact with specific receptors associated with a variety of diseases throughout the body. Their interaction produces pharmacologic effects. According to Zynerba, their development efforts on CBD are not in vain. The use of CBD has produced positive effects on the Central Nervous System. The CBD compound is non-euphoric, non-addictive, does not produce euphoric effects, and is not high on tetrahydrocannabinol (THC).  

Other than that, Zynerba has demonstrated its continued commitment to providing new treatment options for patients battling certain rare neuropsychiatric diseases through increased research efforts. The goal is to advance the science of therapeutic cannabinoids by using an established pharmaceutical manufacturing process.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

FEATURED STORIES

Business19 hours ago

The Green Organic Dutchman Holdings (OTC: TGODF) Releases an Update on its Canadian Securities Exchange Listing

Post Views: 4 The Green Organic Dutchman Holdings (OTC: TGODF) is a top producer of organically-grown, premium certified marijuana, and it...

Business19 hours ago

Next Green Wave Holdings Inc (OTCMKTS: NXGWF) Announces the Resignation of One of Its Directors

Post Views: 55 Next Green Wave Holdings Inc (OTCMKTS: NXGWF) recently announced that a Director had resigned from this position. The...

Business20 hours ago

AFC Gamma Inc (NASDAQ: AFCG) Increases Quarterly Dividend by 13.2% per Share, and the Group Expands its Senior Secured Credit Facility with Devi Holdings, Inc. by $30 Million

Post Views: 26 AFC Gamma Inc (NASDAQ: AFCG) recently announced a dividend for the quarter ending September 30, 2021. The...

Business20 hours ago

TerrAscend Corp (OTCMKTS: TRSSF) Acquisition of Gage Cannabis Receives Pre-Qualification Approval

Post Views: 53 TerrAscend Corp (OTCMKTS: TRSSF) is a leading cannabis operator based in North America that recently announced it had...

Business2 days ago

Jushi Holdings Inc (OTCMKTS: JUSHF) Opens 15th Store in Pennsylvania, Acquires Nature’s Remedy, and Announced Launch of Flower Brands

Post Views: 2 Jushi Holdings Inc (OTCMKTS: JUSHF), through its subsidiary, Franklin Bioscience – SE LLC. BEYOND / HELLO™ Colwyn...

Business2 days ago

FinCanna Capital Corp (OTCMKTS: FNNZF) Set to launch its “Big Fish” Cannabis-Based Edibles Brand

Post Views: 3 FinCanna Capital Corp (OTCMKTS: FNNZF) is an investment corporation for the United States licensed cannabis market that recently...